| Literature DB >> 24484773 |
Lisi Zhu, Menglin Li, Lilong Wei, Xuejiao Liu, Jianrui Yin, Youhe Gao1.
Abstract
BACKGROUND: Fast Fixation is necessary to study real-time protein-protein interactions under physiological conditions. Fast formaldehyde cross-linking can fix transient and weak protein interactions, thereby reducing the number of false negatives but producing great complexity. To reduce this complexity, immunoaffinity purification can Fish out complexes that include particular target proteins, but affinity-based co-purification has a limited capacity to eliminate nonspecific binding to beads and/or antibodies. To Filter out these complexes, SDS-PAGE is used to disrupt non-covalent bonds, thereby eliminating uncross-linked complexes and simultaneously providing molecular weight information for identification.Entities:
Year: 2014 PMID: 24484773 PMCID: PMC3922604 DOI: 10.1186/1477-5956-12-6
Source DB: PubMed Journal: Proteome Sci ISSN: 1477-5956 Impact factor: 2.480
Figure 1Principle of the 4 F strategy. T: target protein, L: ligand. Without staining, the portion of the gel corresponding to molecular weights above that of a single albumin molecule (70 kDa) was excised in six slices using the protein markers as a guide. The slices corresponded to MWs of 70–100 kDa, 100–130 kDa, 130–180 kDa, 180–250 kDa, 250–300 kDa, and greater than 300 kDa. 1. The target protein has to be identified in the same slice as the ligands. 2. The molecular weight of each complex is the sum of the theoretical MWs of the target and the ligand. a) Ligands are not identified in the control, as observed for L1 and L3. b) Target complexes bind to the beads nonspecifically after cross-linking. To be conservative, the ligand should be identified at a MW higher than that of the control (> = 300 kDa) and outside of the neighboring range (250–300 kDa), as for L2. (L2-T-L3 is an example of a complex with interactions other than binary interactions). 3. Proteins identified in the same range as in the control group or in a neighboring range are eliminated as contaminants and are not shown in the figure.
Figure 2Formaldehyde cross-linking of human blood samples. Human blood was incubated with various concentrations of formaldehyde for 5 s or with 10% formaldehyde for various times: (a) samples were analyzed using SDS-PAGE and (b) samples were analyzed using Western blotting with an anti-albumin antibody.
Spectrum counts for albumin and the identified albumin ligands in each molecular weight range
| P02768 | ALBU_HUMANa | | 71.317 | 59 (45) | 184 (68) | 269 (109) | 418 (74) | 328 (70) | 516 (103) |
| P02760 | AMBP_HUMANa | 14 | 39.886 | | 8 | 2 | | 0 (3) | |
| P01024 | CO3_HUMANa | 12, 13, 14 | 188.569 | | 55 | 49 | 43 (31) | | 3 |
| P15924 | DESP_HUMANa | 13 | 334.021 | 3 | | | | 0 (2) | |
| P02671 | FIBA_HUMANa | 11, 12, 13, 14 | 95.656 | 8 | 23 | 10 | 6 (5) | 8 | 5 (15) |
| P69905 | HBA_HUMANa | 13 | 15.305 | 3 | 9 | 10 | 9 | 19 (4) | 16 (8) |
| P01871 | IGHM_HUMANa | 12, 14 | 49.96 | 2 | 8 | 9 | 3 | 3 | 4 (29) |
| P12273 | PIP_HUMANa | | 16.847 | 3 | 7 | | 0 (2) | | |
| P00747 | PLMN_HUMANa | 12, 13, 14 | 93.247 | | | 2 | 3 | 30 (3) | |
| P01023 | A2MG_HUMAN | 12, 14 | 164.613 | 13 | 53 | 47 | | | |
| P02647 | APOA1_HUMAN | 11, 12, 13, 14 | 30.759 | | | | | 3 | 2 |
| P05090 | APOD_HUMAN | 12, 14 | 21.547 | | 7 | | | | |
| P02730 | B3AT_HUMAN | | 102.013 | 3 | 4 | 4 | 2 | 19 | 5 |
| P04040 | CATA_HUMAN | | 59.947 | | | | 2 | | |
| P00450 | CERU_HUMAN | 12, 13, 14 | 122.983 | | | | 2 | | |
| P00751 | CFAB_HUMAN | 11, 12, 13, 14 | 86.847 | | | | | 5 | |
| P16452 | EPB42_HUMAN | | 77.816 | 4 | | | | | |
| Q01469 | FABP5_HUMAN | | 15.497 | | 7 | | | | |
| P02675 | FIBB_HUMAN | 12, 14 | 56.577 | 7 | 30 | 23 | 21 | 15 | 2 |
| P02679 | FIBG_HUMAN | 12 | 52.106 | | 23 | 10 | 7 | 8 | |
| P05155 | IC1_HUMAN | 11, 13, 14 | 55.347 | | | | | 2 | |
| P01857 | IGHG1_HUMAN | 11, 12, 14 | 36.596 | | 8 | 11 | 27 | 31 | 20 |
| P01859 | IGHG2_HUMAN | 11, 12, 14 | 36.505 | | 3 | 6 | 9 | | |
| P01860 | IGHG3_HUMAN | 12, 14 | 42.287 | | | 8 | 19 | 22 | 14 |
| P01861 | IGHG4_HUMAN | 14 | 36.431 | | | | | 19 | |
| P01834 | IGKC_HUMAN | 11, 12, 14 | 11.773 | | 2 | | | | 5 |
| B9A064 | IGLL5_HUMAN | | 23.391 | | | 3 | | | |
| P06312 | KV401_HUMAN | | 13.486 | | 17 | | | | |
| P0CG04 | LAC1_HUMAN | 12, 14 | 11.512 | | | | | 4 | 7 |
| P47929 | LEG7_HUMAN | | 15.123 | | 2 | | | | |
| P32119 | PRDX2_HUMAN | | 22.049 | | | | | 4 | 4 |
| P31151 | S10A7_HUMAN | | 11.578 | | 8 | | | | |
| P06702 | S10A9_HUMAN | 14 | 13.291 | | 10 | | | | |
| P29508 | SPB3_HUMAN | | 44.594 | | 9 | | | | |
| P04004 | VTNC_HUMAN | 12, 13, 14 | 55.069 | | | | 3 | | |
| P25311 | ZA2G_HUMAN | 13 | 34.465 | | 4 | | | | |
| Total spectrum counts in each MW range | 40 | 288 | 184 | 147 | 173 | 71 | |||
aAlbumin and ligands also identified in the control.
The spectrum counts for the control are listed in brackets.